Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (METRIC): a randomized multicenter study

The METRIC study (NCT#0199733) explored a novel antibody-drug conjugate, glembatumumab vedotin (GV), targeting gpNMB that is overexpressed in similar to 40% of patients with triple-negative breast cancer (NBC) and associated with poor prognosis. The study was a randomized, open-label, phase 2b study that evaluated progression-free survival (PFS) of GV compared with capecitabine in gpNM-Boverexpressing TNBC. Patients who had previously received anthracycline and taxane-based therapy were randomized 2:1 to receive, GV (1.88 mg/kg IV q21 days) or capecitabine (2500 mg/m(2) PO daily d1-14 q21 days). The primary endpoint was RECIST 1.1 PFS per independent, blinded central review. In all, 327 patients were randomized to GV (213 treated) or capecitabine (92 treated). Median PFS was 2.9 months for GV vs. 2.8 months for capecitabine. The most common grade >= 3 toxicities for GV were neutropenia, rash, and leukopenia, and for capecitabine were fatigue, diarrhea, and palmar-plantar erythrodysesthesia. The study did not meet the primary endpoint of improved PFS over capecitabine or demonstrate a relative risk/benefit improvement over capecitabine.

Automated summary

The METRIC study investigated a novel antibody-drug conjugate, glembatumumab vedotin (GV), targeting gpNMB for the treatment of triple-negative breast cancer. However, it did not demonstrate improved progression-free survival over capecitabine in the study.